Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for individuals and families affected by rare neurological diseases.
Revenue: The company reported revenue under licensing agreements of $0 for the year ended December 31, 2025, compared to $925 (in thousands of U.S. dollars) in 2024.
Earnings Per Share (EPS): The net loss per share, basic and diluted, was $(4.24) in 2025, representing a slight change from $(4.28) in 2024.
Neurogene reported a net loss of $90.4 million for 2025, an increase from $75.1 million in 2024.
Research and development expenses totaled $75.0 million for the year.
The company holds $269.0 million in cash, cash equivalents, and short-term investments, which is expected to fund planned operations through the first quarter of 2028.